Ireland
--:--IST
Recruiting Phase 3

An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin

NCT07845071 · tracked via the Priya Life Science USA tracker
Sponsor
Adneuris Therapeutics, Inc
Phase
Phase 3
Started
2026-09-22
Last updated
2026-10-23

Condition(s) studied

Pain

Investigational drug(s) / intervention(s)

Cebranopadol 400 ug →

Cebranopadol 400 ug: Participants receive Cebranopadol 400 mcg once per day for 14 days or until pain resolves, whichever occurs first.

Study summary

The purpose of this study is to evaluate the safety and effectiveness of cebranopadol in treating acute pain.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Adults 18 to 75 years of age. * Able to provide informed consent. * Experiencing moderate to severe acute pain related to: 1) An ambulatory surgical procedure expected to cause pain lasting at least 72 hours, or 2) A traumatic or non-traumatic musculoskeletal condition. * Have a pain score of at least 4 on a 0 to 10 pain rating scale before starting study treatment. * Willing and able to comply with study requirements Exclusion Criteria: * Chronic pain condition that requires ongoing pain medication. * Significant medical or psychiatric condition that could affect participation or study results. * History of substance use disorder or misuse of alcohol or drugs. * Current use of medications that may interfere with the study drug or pain assessments. * Known allergy or intolerance to cebranopadol or permitted rescue pain medications. * Pregnant or breastfeeding. * Participation in another clinical trial or receipt of an investigational drug within the protocol-defined period before study entry. * Any condition that, in the investigator's opinion, would make participation unsafe or interfere with study assessments.

Primary outcome measure(s)

  • Sum of pain intensity differences through 48 hours (SPID48) — From 0 through 48 hours
    Sum of pain intensity differences through 48 hours (SPID48), calculated from NPRS assessments collected following the first administration of cebranopadol.

Trial sites (15)

FacilityCityRegionStatus
Adneuris Site 001115 Phoenix Arizona Recruiting
Adneuris Site 001118 Riverside California Recruiting
Adneuris Site 001119 Longmont Colorado Recruiting
Adneuris Site 001122 Savannah Georgia Recruiting
Adneuris Site 001123 O'Fallon Illinois Recruiting
Adneuris Site 001125 Annapolis Maryland Recruiting
Adneuris Site 001120 Oradell New Jersey Recruiting
Adneuris Site 001124 Tulsa Oklahoma Recruiting
Adneuris Site 001110 Bellaire Texas Recruiting
Adneuris Site 001117 Forney Texas Recruiting
Adneuris Site 001104 McAllen Texas Recruiting
Adneuris Site 001116 Plano Texas Recruiting
Adneuris Site 001111 San Antonio Texas Recruiting
Adneuris Site 001121 San Antonio Texas Recruiting
Adneuris Site 001101 Salt Lake City Utah Recruiting

More Adneuris Therapeutics, Inc. trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07845071 on ClinicalTrials.gov ↗ ← All trials in the USA